India & Brazil Deepen Pharmaceutical & Medical Product Regulation Ties with a New MoU

Officials have indicated that this partnership will focus on capacity building, knowledge sharing, and convergence of regulatory frameworks, strengthening pharmacovigilance systems, and enhancing oversight of medical products across both markets.

India and Brazil have signed a new Memorandum of Understanding to enhance cooperation in pharmaceutical and medical product regulation, signalling a strategic push to align standards, strengthen oversight, and improve access to safe and affordable healthcare solutions in both countries.

The agreement was exchanged at Hyderabad House in the presence of Prime Minister Narendra Modi and Brazilian President Luiz Inacio Lula da Silva.

This development builds on longstanding India-Brazil engagement, particularly within multilateral platforms such as BRICS and the Global South coalition, where both nations have consistently advocated for equitable access to medicines and resilient healthcare systems.

India, often referred to as the “pharmacy of the world,” plays a critical role in supplying affordable generic medicines globally, while Brazil has a robust regulatory ecosystem led by ANVISA, known for its stringent quality and safety standards.

The MoU, signed between the Central Drugs Standard Control Organisation (CDSCO) and Brazil’s ANVISA, establishes a structured mechanism for cooperation across a wide spectrum of medical products.

These include pharmaceutical ingredients, finished drugs, biologicals, and medical devices. By enabling information exchange and regulatory coordination, the agreement seeks to harmonise approaches and reduce duplication in regulatory processes.

Officials have indicated that this partnership will focus on capacity building, knowledge sharing, and convergence of regulatory frameworks. Such collaboration is expected to improve the efficiency of approval processes, strengthen pharmacovigilance systems, and enhance oversight of medical products across both markets.

The Ministry of Health and Family Welfare has emphasised that the agreement reflects a shared priority: ensuring that citizens have access to safe, effective, and high-quality medical products. In addition to regulatory alignment, the MoU is expected to bolster supply chain resilience.

By fostering mutual trust and technical collaboration, the MoU is expected to unlock new opportunities for joint initiatives, research partnerships, and market access.

Stay tuned for more such updates on Digital Health News